Trial Profile
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jul 2022
Price :
$35
*
At a glance
- Drugs Pyrotinib (Primary) ; Capecitabine; Lapatinib
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 07 Jun 2022 Results of pooled analysis from (NCT01937689,NCT02361112,NCT02422199,NCT03080805) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results (N=63), pooled analysis of three trials, assessing efficacy of pyrotinib plus capecitabine pts with HER2-positive, trastuzumab-resistant relapsed or metastatic breast cancer, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results of pooled analysis investigating the efficacy of pyrotinib plus capecitabine as first-line treatment in patients with HER2-positive relapsed or metastatic breast cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology